American Heart Journal
Volume 152, Issue 3 , Pages 454.e1-454.e8 , September 2006

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance

  • Judith M. Kramer, MD, MS

      Affiliations

    • Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Judith M. Kramer, MD, MS, Duke Center for Education and Research on Therapeutics, Duke University Medical Center, PO Box 17969, Durham, NC 27715.
  • ,
  • Bradley Hammill, MA

      Affiliations

    • Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC
  • ,
  • Kevin J. Anstrom, PhD

      Affiliations

    • Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC
  • ,
  • Donald Fetterolf, MD, MBA

      Affiliations

    • Council for Affordable Quality Healthcare, Washington, DC
  • ,
  • Richard Snyder, MD

      Affiliations

    • Council for Affordable Quality Healthcare, Washington, DC
  • ,
  • John P. Charde, MD

      Affiliations

    • Council for Affordable Quality Healthcare, Washington, DC
  • ,
  • Barbara S. Hoffman, PA-C, MBA

      Affiliations

    • Council for Affordable Quality Healthcare, Washington, DC
  • ,
  • Nancy Allen LaPointe, PharmD

      Affiliations

    • Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC
  • ,
  • Eric Peterson, MD, MPH

      Affiliations

    • Duke Center for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC

Received 30 January 2006 ,Accepted 17 February 2006.

References 

  1. American Heart Association . Heart Disease and Stroke Statistics—2006 Update. Published online before print January 11, 2006. Available online at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600v1.pdf
  2. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  3. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. JAMA. 1988;260:2088–2093
  4. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737
  5. Dargie HJ for the CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  6. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115–121
  7. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623–629
  8. Bradford WD, Chen J, Krumholz HM. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics. 1999;15:257–268
  9. Mehta RH, Montoye CK, Gallogly M, et al. for the GAP Steering Committee of the American College of Cardiology Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA. 2002;287:1269–1276
  10. Labresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203–209
  11. JCAHO Website. Available at: http://www.jcaho.org/quality+check/index.htm. Accessed January 27, 2006.
  12. National Committee for Quality Assurance . The State of Health Care Quality: 2003. Available at: http://www.ncqa.org/communications/State%20Of%20Managed%20Care/SOHCREPORT2003.pdf[Accessed January 27, 2006]
  13. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589–1595
  14. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438–444
  15. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117:73–81
  16. Pederson TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med. 1985;313:1055–1058
  17. Steinbrook R. The prescription-drug problem. N Engl J Med. 2002;346:790
  18. Tseng CW, Brook RH, Keeler E, et al. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952–960
  19. NCQA . HEDIS 2004 Final NDC Lists. Available at: http://www.ncqa.org/Programs/HEDIS/legal2004.htm[Accessed January 27, 2006]
  20. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–461
  21. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993;270:742–744
  22. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–467
  23. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74:511–544
  24. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868–2879
  25. Allen LaPointe NM, Jollis JG. Medication errors in hospitalized cardiovascular patients. Arch Intern Med. 2003;163:1461–1466
  26. Vaccarino V, Krumholz HM, Yarzebski J, et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001;134:173–181
  27. American Heart Association website. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3017091. Accessed January 27, 2006.
  28. National Heart Lung and Blood Institute website. Available at: http://www.nhlbi.nih.gov/health/hearttruth/. Accessed January 27, 2006.
  29. Achman L, Gold M. Medicare + Choice plans continue to shift more costs to enrollees. April 2003. Available at: http://www.cmwf.org/usr_doc/achman_m+cshiftcosts_628.pdf[Accessed January 27, 2006]
  30. Council for Affordable Quality Healthcare website. Available at: http://www.caqh.org/life.html. Accessed January 27, 2006.
  31. Jha AK, Schneider EC. From motives to results: improving the effectiveness of quality improvement. Am J Med. 2004;117:359–361

 Duke investigators are supported in part by grant HS010548 from the Agency for Healthcare Research and Quality, Rockville, Md.

 Funding/Support: Participating health plans contributed personnel time for work groups (listed in Appendix B) and for collection and reporting of data. The Council for Affordable Quality Healthcare (CAQH) contracted with PricewaterhouseCoopers to aggregate de-identified data submitted by health plans and to provide feedback to the plans on the quality of data. The CAQH also provided an honorarium to Duke University for its investigators' time in analyzing and interpreting the aggregated data and preparing the manuscript.

 Role of the Sponsor: CAQH provided a project manager to support the CAQH Cardiac and Measurement Work Groups. Final decisions on study design and technical specifications were made by the CAQH Cardiac and Measurement Work Groups. The CAQH allowed Duke investigators full independence in the analysis and interpretation of the data. The manuscript was prepared by Duke investigators. Contributing authors provided review and approval.

 Guest editor of this manuscript is Deepak L. Bhatt, MD.

PII: S0002-8703(06)00169-4

doi: 10.1016/j.ahj.2006.02.030

American Heart Journal
Volume 152, Issue 3 , Pages 454.e1-454.e8 , September 2006